ABSTRACT
INTRODUCTION
Angiogenesis drives tumor progression [1] , and pathways involving vascular endothelial growth factors (VEGFs) and its receptors (VEGFRs) promote tumor angiogenesis [2] . Bevacizumab (Bev) is a humanized anti-VEGF-A neutralizing monoclonal antibody, and the combination regimen of add-on Bev with pre-existing chemotherapeutic agents provide improved clinical benefits more than chemotherapy alone in several malignancy types [3] [4] [5] . Unlike chemotherapeutic agents, the anti-angiogenesis strategy should result in far less drug resistance [6, 7] . However, Bev-combined chemotherapy still could not overcome drug resistance in clinical settings [8, 9] . CD11b + /Gr-1 + cells, which include neutrophils, macrophages, and myeloid-derived suppressor cells (MDSCs), promote tumor escape from anti-VEGF therapy [10, 11] . This process likely involves at least two independent mechanisms: bypassing anti-VEGFmediated anti-angiogenesis via secretion of the alternative angiogenic factor Bv8 [12] and a MDSC-mediated,
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Th17-dependent immune suppressive pathway [13] . Both mechanisms were shown to be mediated via intratumoral recruitment of myeloid cells by granulocyte-colony stimulating factor (G-CSF) [12, 13] . In the present study, we used a mouse model to investigate a possible alternative pathway that may promote tumor resistance to anti-VEGF therapy.
RESULTS

Anti-VEGF treatment increased the number of intratumoral CD11b
high /Gr-1 high cells Shojaei et al. used B16F1 melanomas and LLC murine lung carcinomas to show resistance to anti-VEGF antibody treatment is associated with intratumoral MDSC accumulation [11] . Because Gr-1 is a cell surface marker that reflects the immune suppressive activity of MDSCs in tumor models [14] [15] [16] , we used CD11b and Gr-1, rather than Ly6G/Ly6C, to identify the subpopulation of MDSCs. The anti-VEGF treatment was effective against B16F1 tumors associated with a very small amount of CD11b high / Gr-1 high , ( Figure 1A ) [14] [15] [16] . In contrast, the anti-VEGF treatment accelerated intratumoral MDSC accumulation ( Figure 1B) .
Next, because MDSCs show at least two distinct phenotypes, namely PMN-and monocytic (M)-MDSCs, we investigated the effect of anti-VEGF treatment on these populations using LLC tumors. Anti-VEGF treatment increased the ratio of CD11b high /Gr-1 high PMN-MDSCs ( Figure 1C ).
Capecitabine, a prodrug of 5-FU, restored the antitumor effect of anti-VEGF
Since 5-FU can selectively kill MDSCs and enhance T-lymphocyte-mediated antitumor immune responses [17] , we evaluated the effect of 5-FU and the clinically available prodrug of 5-FU, capecitabine, on LLC tumor growth under anti-VEGF treatment. Capecitabine, but not 5-FU, demonstrated a combined antitumor effect with anti-VEGF ( Figure 2A ). In addition, capecitabine diminished the intratumoral accumulation of PMN-MDSCs ( Figure  2B ) and circulating PMN-MDSCs ( Figure 2C , right). 5-FU only partially inhibited these same parameters ( Figure 2C , left).
G-CSF, but neither IL-17 nor Bv8, promoted intratumoral PMN-MDSC recruitment and antitumor angiogenesis in the LLC tumor model
We screened for cytokines/chemokines expressed by LLC tumors in vivo that stimulate anti-VEGFmediated PMN-MDSC recruitment. G-CSF and CCL2, but not IL-17A or Bv8, were increased by the anti-VEGF treatment, and capecitabine reduced those upregulations ( Figure 3A) . The selective antagonist of the CCL2 receptor CCR2 (RS102895) at the appropriate dose [18] did not affect either tumor growth or PMN-MDSC accumulation (data not shown). Anti-mouse G-CSF-neutralizing mAb inhibited tumor growth and PMN-MDSC accumulation ( Figure 3B ) under anti-VEGF administration, confirming G-CSF promotes intratumoral PMN-MDSC recruitment during anti-VEGF therapy [11] . G-CSF expression increased after anti-VEGF treatment in LLC tumor lysate, while IL-17A expression was low ( Figure 4A ). Bv8 protein was detected, and neither anti-VEGF nor capecitabine treatment changed its protein level ( Figure 4B) .
We focused on an Bv8-independent mechanism of tumor angiogenesis, as an IL-17-mediated immunerelated mechanism appears unlikely. We assessed the platelet and endothelial cell adhesion molecule (PECAM)-1-positive vascular surface area in each tumor using an image analyzer. Anti-VEGF therapy alone did not inhibit tumor angiogenesis, whereas the addition of anti-G-CSF neutralizing antibody reduced the vascular surface area ( Figure 4C ). Tumor sections treated with anti-VEGF combined with capecitabine displayed similar results ( Figure 4D ), suggesting that an anti-VEGF/PMN-MDSCs/ G-CSF axis may contribute to the Bv8-independent angiogenic escape induced by anti-VEGF treatment.
Intratumoral MDSCs have PyNPase activities and the proangiogenic factor TP
Pyrimidine nucleotide phosphorylases (PyNPases), composed of thymidine phosphorylase (TP) and uridine phosphorylase (UP), are proangiogenic factors [19] [20] [21] and capecitabine converting enzymes [22, 23] . We investigated PyNPase activity in various cells, including MDSCs. The capecitabine-sensitive human colorectal cancer cell line HCT116 [22] demonstrated high PyNPase activity as a positive control, whereas CD45 + cells derived from murine spleen cells showed no activity ( Figure 5A ). The LLC cells and PMN-and M-MDSCs sorted from the LLC tumors had high PyNPase activity. The in vivo capecitabine treatment reduced the intratumoral content of TP independent of anti-VEGF treatment ( Figure 5B), indicating that capecitabine could eliminate PyNPases in tumors.
Impairment of capecitabine effects under anti-VEGF in PyNPases TP
−/−
/UP −/− double-deficient mice
We assessed TP activity in host-originated PMNMDSCs, using LLC tumors bearing TP The potential role of TP (platelet-derived endothelial cell growth factor [PD-ECGF]) in tumor angiogenesis in VEGF-negative tumor tissue was first suggested for colon cancer [19, 25, 26] . Since then, a number of studies have reported various tumor types and tumor infiltrating macrophages (TAMs) and lymphocytes to be the cellular sources of TP [27] . The present study is the first to determine that MDSCs, in particular the PMN type, are the functionally essential TP-expressing cells in tumors during anti-VEGF therapy.
Considering our present findings and the good safety and efficacy profiles of the combination of capecitabine and bevacizumab in phase III trials [4, 28] , the observed partial effect of capecitabine on the restoration of antiangiogenesis and inhibition of tumor growth during anti-VEGF treatment suggests more study may enable further optimization of anti-VEGF therapy to provide greater clinical benefit.
The capecitabine dose used in this study almost eliminated PMN-MDSCs in peripheral blood, but this effect was partially reduced in intratumoral areas (Figure 2 ). This may be due to (i) an insufficient distribution of capecitabine to the whole tumor tissue even though the systemic dose of it was sufficient, and/ or (ii) the recruitment of other cells that are insensitive to capecitabine/5-FU and express TP/UP to tumor microenvironment. The latter might be likely, because CD68-positive tumor-associated macrophages (TAMs) were identified as the dominant cell source of TP/ PD-ECGF in human colorectal cancer tissue [25] . Capecitabine reversed tumor escape from anti-VEGF, and may be a favorable chemotherapeutic agent that should be combined with bevacizumab in clinical settings (Supplementary Figure 1) .
MATERIALS AND METHODS
Cell lines and culture conditions
The murine lung cancer (LLC) and murine melanoma (B16F1) cell lines were obtained in 2004 from the American Type Culture Collection (ATCC; Rockville, MD). The human colorectal cancer cell line HCT116 was obtained in 1990 from the ATCC. The LLC and B16F1 cells were cultured in high-glucose Dulbecco's Modified Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 4 mM glutamine, and maintained at 37° C in 5% CO 2 . The HCT116 was cultured in McCoy's 5A Medium supplemented with 10% FBS and maintained at 37° C in a 5% CO 2 . All cell lines were passaged up to 20 times. All cell lines were authenticated using STR analyses, and were routinely tested for mycoplasma contamination using PCR-based detection methods in Central Institute for Experimental Animals (Kanagawa, Japan).
Mice
Male 5-to 9-week-old C57BL/6 mice were obtained from KBT Oriental (Charles River Grade, Tosu, Saga, Japan). Male 7-week-old thymidine phosphorylase and uridine phosphorylase double-deficient mice (TP
) on the C57BL/6 background were provided by Prof. Furukawa (Department of Cancer Chemotherapy, Kagoshima University, Kagoshima) [24] . The mice were kept under specific pathogen-free and humane conditions, 
Flow cytometric analysis
Tumors were excised from control-and anti-VEGFtreated mice, and single cell suspensions were obtained by mincing tumors and homogenizing by disruption and digestion with a gentle MACS™ Dissociator and Tumor Dissociation Kit for mouse (Miltenyi Biotec, Bergisch Gladbach, Germany). Peripheral blood was pretreated with VersaLyse™ lysing solution for red blood cells lysis (Beckman Coulter, Indianapolis, IN).
Cells were stained with the following FITC-, PE-, PE-Cy5-, BV785, or Alexa647-conjugated monoclonal antibodies: mouse CD11b, Gr1, CD45 (BioLegend, San Diego, CA), G-CSF (eBioscience, San Diego, CA), and TP (Proteintech, Chicago, IL). The appropriate conjugated isotype-matched Immunoglobulin Gs (IgGs) were used for control. Intracellular cytokine staining was performed with the Cell Fixation/Permeabilization kit (BD Biosciences, Franklin Lakes, NJ). Cells were analyzed using a FACSAria™ cell sorter and an LSRFortessa™ cell analyzer (BD Biosciences) and FlowJo 7.6 software (Tree Star, San Carlos, CA).
Immunohistochemistry
We evaluated microvessel density in the tumor tissue by performing immunohistochemical staining of PECAM-1 (rat anti-mouse PECAM-1 mAb, clone MEC 13.3; BD Biosciences). Tumor samples were collected at the end of the study. Immunohistochemistry was performed as described previously [29] . The microvessel density (%) was calculated from the ratio of the PECAM-1-positive staining area to the total observation area in the viable region. Positive staining areas were calculated using the imaging analysis software Tissue Studio ® (Definiens, Munich, Germany).
Immunoassays
Tumor homogenates collected at the end of the study were analyzed with the BD™ Cytometric Bead Array (BD Biosciences). The concentrations of mouse IL-17A, G-CSF, CXCL12, CXCL5, and CCL2 were measured by a Quantikine ELISA kit (R&D Systems). Bv8 was quantified using the mouse prokineticin-2 (Bv8) ELISA kit (Cusabio Biotech, Selangor, Malaysia). The protein amount of TP was quantified using a specific ELISA kit (Cloud-Clone, Katy, TX).
PyNPase enzymatic activity assay
Cells were homogenized in 10 mM Tris buffer (pH 7.4), containing 15 mM NaCl, 1.5 mM MgCl 2 , and 50 μM potassium phosphate. The homogenate was then centrifuged at 105,000 g for 90 min. The supernatant was dialyzed overnight against 20 mM potassium phosphate buffer (pH 7.4) containing 1 mM β-mercaptoethanol and used as a source of crude enzyme. All procedures were carried out below 4° C. The reaction mixture (120 μl) for the assay of the enzyme activity contained 183 mM potassium phosphate (pH 7.4), 10 mM 5′-dFUrd, and the crude enzyme from cells. The reaction was carried out at 37° C for 60 min, and then terminated by adding 360 μl of methanol. After removal of the precipitate by centrifugation, the amount of 5-FUra produced in the supernatant was measured with the My5-FU assay (Saladax Biomedical, Bethlehem, PA). The dThdPase and UPase activities are expressed as ng of 5-FUra converted/10 5 cells/h.
Statistical analysis
All data are expressed as the mean ± standard error of the mean (SEM). The Wilcoxon test was used, and P-values < 0.05 were accepted as significant. Statistical analyses were carried out using JMP, version 10 (SAS Institute, Cary, NC).
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